HCXT-2001 Tablets(A)
Phase 1
HCXT-2001 Tablets(A) is one of 44 therapeutic programs targeting Psoriasis. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
107 competitors in Psoriasis
#DrugCompanyPhaseTrials
1Daliresp
AstraZenecaPhase 3
Zasocitinib
TakedaPhase 3
TAK-279
TakedaPhase 3
Ponvory
VVanda Pharmaceuticals
Phase 3
SYHX1901
CCSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3
Vunakizumab (IL-17A Inhibitor)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
SHR-1314
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
HS-10374
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 3
ICP-488
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
IDP-118 Lotion
BBausch Health Americas, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Psoriasis1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for HCXT-2001 Tablets(A). EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]